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In this paper, we provide recommendations on the management of cardiovascular disease (CVD) 
among patients with confirmed or suspected coronavirus disease (COVID-19) to facilitate 
the decision making of healthcare professionals in low resource settings. The emergence of 
novel coronavirus disease, also known as Severe Acute Respiratory Syndrome-Coronavirus-2 
(SARS-CoV-2), has presented an unprecedented global challenge for the healthcare community. 
The ability of SARS-CoV-2 to get transmitted during the asymptomatic phase and its high 
infectivity have led to the rapid transmission of COVID-19 beyond geographic regions, leading 
to a pandemic. There is concern that COVID-19 is cardiotropic, and it interacts with the car-
diovascular system on multiple levels. Individuals with established CVD are more susceptible 
to severe COVID-19. Through a consensus approach involving an international group this WHF 
statement summarizes the links between cardiovascular disease and COVID-19 and present 
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some practical recommendations for the management of hypertension and diabetes, acute coro-
nary syndrome, heart failure, rheumatic heart disease, Chagas disease, and myocardial injury for 
patients with COVID-19 in low-resource settings. This document is not a clinical guideline and 
it is not intended to replace national clinical guidelines or recommendations. Given the rapidly 
growing burden posed by COVID-19 illness and the associated severe prognostic implication of 
CVD involvement, further research is required to understand the potential mechanisms linking 
COVID-19 and CVD, clinical presentation, and outcomes of various cardiovascular manifesta-
tions in COVID-19 patients.
Keywords: cardiovascular disease; coronavirus; COVID-19; low resource settings; low income 
countries; middle income countries
Introduction
In late 2019, an outbreak of viral pneumonia was reported in Wuhan, Hubei province, China. Caused by a 
new coronavirus called SARS-COV-2 (initially 2019-nCOV), the infection spread from a local seafood market 
where wild animals, such as bats –the possible reservoir of the virus, were sold [1]. Although initial cases 
may have been infected through zoonotic exposure, infection spread through human-to-human transmis-
sion, mainly via respiratory droplets and close interpersonal contact with those infected, including asymp-
tomatic carriers [2, 3]. On average, each carrier transmits the disease to 2-3 other people [4–6]. The incuba-
tion period is four to five days but may reach 14 days [6]. Affected patients have fever, dry cough, dyspnea, 
headache and pneumonia [7], in a similar clinical picture of those affected by the SARS epidemic in 2003 
[8]. Atypical features include a low prevalence of sneezing and gastrointestinal symptoms including nausea 
in about a third of patients. 
This new disease, now called COVID-19 [9], was declared a pandemic by the World Health Organization 
(WHO) on March 11th. To date, COVID-19 has spread to 212 countries/ areas/ or territories, affected 3, 672, 
238 persons and resulted in the death of 254, 045 patients (Figure 1) [10], with substantially growing 
numbers of infections and deaths as the pandemic progresses. Although 80% of all patients with confirmed 
COVID-19 may have only mild or moderate symptoms, the case-fatality ratio is highly variable depending 
on how the cases are defined, the testing practices, the health system access and other unknown factors. 
Reports provide a range between 2-7% overall and may be as high as 20% in the elderly [11]. 
The interaction between COVID-19 and the cardiovascular system has been a subject of special attention. 
Figure 1: Global Map of COVID-19 pandemic by region.
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Patients with pre-existing cardiovascular disease (CVD), hypertension, or diabetes mellitus appear to be 
at increased risk of having severe form of the disease. The involvement of the cardiovascular system had 
already been described in other epidemics caused by corona viruses [12]. In COVID-19, patients with or at 
risk for CVD seem to be at a higher risk of more severe disease, the need of intensive care unit (ICU) [13], 
and mortality [14, 15]. 
There are different potential mechanisms suggested for the link between COVID-19 and CVD. The poten-
tial pathophysiological links between COVID-19 and CVD include virus-induced inflammation, increase risk 
of thrombosis, ischemia due to increased oxygen demand, microvascular ischemic injury and the accelerated 
immunologic response (cytological storm) mediated injury [16]. 
Also, there have been reports of cardiac complications in COVID-19 patients including myocardial injury, 
acute coronary events and heart failure. It has been reported that patients with these complications (includ-
ing troponin elevation) are at a higher risk of mortality [17]. 
Different organizations have issued recommendations for the management of patients with cardiovascu-
lar disease at the time of COVID-19 pandemic [18–20]. 
The management of more seriously ill patients with COVID-19 requires resources, like medical supplies, 
ventilators, personal protective equipment (PPE), that could become limited, even in high-income countries. 
Dealing with this situation in countries where resources are scarce is even more challenging. In the context 
of COVID-19, low resource setting refers to a setting with limited capacity to diagnose, quarantine, isolate, 
and treat COVID-19 patients and the cardiovascular complications or their illness, as well as acute coronary 
syndromes, including the use of invasive diagnostic or treatment support for acute coronary syndromes in 
both COVID-19 positive and negative patients.
The unprecedented burden of COVID-19 on health systems threatens to exceed hospital capacity, making 
it challenging to care for other emergencies requiring hospitalization, such as acute coronary syndromes 
(ACS). 
In order to support WHF members, particularly those working in low-resource settings, a writing group 
including members of the WHF Science Committee and WHF Emerging Leaders under the leadership of 
the Chair of the Science Committee and WHF President developed a statement with recommendations to 
manage patients with CVD and COVID19. It is important to emphasize that this document is not a clini-
cal guideline and should not replace established national clinical guidelines and recommendations nor 
should override the individual responsibility of health care professionals when managing patients with 
these conditions. 
To develop this document, we looked at relevant guidelines, reports and recommendations and through a 
consensus process we agreed on key recommendations on the following topics: general recommendations, 
hypertension and diabetes, acute coronary syndrome, heart failure (including Rheumatic Heart Disease and 
Chagas Disease), and myocarditis. 
General recommendations
COVID-19 patients need to be triaged based on disease severity with patients with moderate and severe 
disease admitted in segregated ward/hospital depending on the available infrastructure. These patients also 
need to be triaged based on co-morbidities like hypertension, diabetes, prior cardiovascular or respiratory 
disease, renal failure and cancer to identify patients with a higher likelihood to have severe disease. Below 
are some broad guidelines with particular reference to low resource settings.
1. Hypertension and diabetes management in COVID-19 positive patients
The cardiovascular manifestations of severe acute respiratory syndrome corona virus -2 (SARS-CoV 2) infec-
tion remain under investigation, however, early evidence from several epidemiological studies suggests that 
patients with CVD or risk factors including hypertension and diabetes have up to a 3-fold increased risk 
for severe morbidity and mortality [18–20]. Early genomic studies into the pathogenesis of cardiovascular 
involvement in COVID 19 infection have indicated a possible mechanism involving the angiotensin-con-
verting enzyme 2 (ACE-2) receptor which is expressed in epithelial cells in the lungs, heart, intestines, and 
kidneys [21–26]. 
The SARS CoV-2 binds ACE-2 receptors expressed on epithelial tissues and uses that as its main functional 
component to gain entry to lungs and myocardium – a hypothesis largely formulated based on animal 
models [21–26]. ACE-2 is an important component of the renin-angiotensin-aldosterone system (RAAS) 
which cleaves angiotensin-II – a vasoconstrictor into angiotensin – a vasodilator. It serves to counterbalance 
the effects of angiotensin converting enzyme (ACE) which converts angiotensin I hormone into angiotensin 
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II. Several prior studies have shown that angiotensin converting enzyme inhibitors/angiotensin II recep-
tor blockers (ACE-i/ARB) lead to upregulation of ACE-2 enzyme therefore enhancing vasodilatory effects 
of renin and angiotensin blockade treatments [21–26]. Therefore, theoretically the upregulation of ACE2 
activity in COVID-19 patients on RAAS treatment may create a higher functional substrate for the virus to 
bind to and cause severe organ damage. However, this is not borne out in observational studies published 
recently [27]. 
In a recent analysis from Lombardy region of Italy that compared 6,272 people with confirmed SARS-
CoV-2 infection with 30,759 controls matched by age, sex, and municipality of residence [28, 29]. It was 
shown neither ACE inhibitors nor ARBs were associated with the probability of SARS-CoV-2 infection [28].
A review based on a database analysis of an international registry from 169 hospitals located in 11 coun-
tries in Asia, Europe, and North America studied the effects of treatment on outcomes of these patients 
who had either died in the hospital or survived to hospital discharge among 8,910 patients of COVID-19 
[30]. It was revealed in this analysis that age greater than 65 years, coronary artery disease, congestive heart 
failure, history of cardiac arrhythmia, chronic obstructive pulmonary disease, and current smoking were 
associated with an increased risk of in-hospital death. Female gender was associated with better outcomes. 
Furthermore, neither ACE inhibitors nor ARBs were associated with an increased risk of in-hospital death. 
A secondary analysis that was restricted to patients with hypertension (those for whom an ACE inhibitor or 
ARB would be indicated) also did not show harm.
Based on available evidence we recommend that treatment with ACE inhibitors and ARBs should be con-
tinued in patients receiving it for hypertension management. This is in line with a similar recommendation 
by other cardiac societies like ACC and ESC.
Diabetes has also been identified as a significant comorbid condition associated with worse outcomes in 
COVID-19 infected patients [19, 20, 31]. In general, there is a consensus that good glycemic control both in 
hospitalized and non-hospitalized COVID-19 infected patients is key to reduce severe morbidity and mortal-
ity from the infection like studies from other systemic infections including influenza [19, 31]. Thus, guide-
lines for diabetes management and glycemic control measures as before should be followed.
2. Acute Coronary Syndrome
An ACS diagnosis should be based on history, the electrocardiogram (ECG), and troponin levels. However, 
classic symptoms and presentation of ACS may be overshadowed in the context of COVID-19, potentially 
leading to under-diagnosis. Because troponin elevation may be present at presentation in 7%–28% [17, 
20, 32–34] of patients with COVID-19, even in the absence of an ischemic etiology, the clinical history and 
ECG must be considered in the interpretation of troponin results. It is also essential to have serial troponin 
measurements to determine whether the myocardial injury reflected by the elevated troponin value is acute 
or chronic. 
The rule should be ACS treatment according to the guidelines. Even rapid COVID-19 tests cannot delay 
ST-segment elevation myocardial infarction (STEMI) treatment. Each patient must be treated as potentially 
infected. Special precautions should apply to patients with high fever and contact with infected COVID-19. 
It needs to be emphasised that facilities must have separate facilities in place for dealing with COVID-19 
cardiac patients and non COVID-19 cardiac patients including catheterization laboratories. 
Overarching issues 
•	 A dedicated infrastructure and process are needed for management of ACS in patients with 
COVID-19. Invasive management should be reserved for critical patients provided that the facility 
has systems in place for non-transmission of coronavirus during transport and treatment.
•	 If existing hospitals have cardiac units with more than one catheterization laboratory, one lab could 
be designated for management of COVID-19 positive or suspected COVID-19 patients. The catheteri-
zation lab needs proper terminal cleaning after managing a COVID-19 patient.
•	 Information on where management is available for suspected or diagnosed COVID-19 patients with 
ACS must be clearly circulated. Testing for diagnosis of COVID-19 must be available at the facilities 
managing the ACS patients.
Invasive management; any type of catherization procedure – diagnostic or intervention – if the patient is 
hemodynamically stable is deferred.
Reperfusion therapy in ACS (e.g. STEMI) should consider the clinical presentation, risk to treating medical 
personnel, staff availability and the availability of high dependency beds in a hospital. Patients with coronary 
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artery disease may be at increased risk because of coronary plaque rupture secondary to virally induced 
systemic inflammation. Use of plaque stabilizing agents (aspirin, statins, beta-blockers, and angiotensin-
converting enzyme inhibitors) has been suggested as a possible therapeutic strategy. Anti-platelet therapy 
may be advised to treat the pro-coagulant effects of systemic inflammation that may increase the likelihood 
of stent thrombosis.
Current recommendations for ACS management
Confirmed COVID-19 infections:
•	 STEMI: Low risk STEMI patients, consider thrombolysis as the treatment of choice. Cardiac catheteri-
zation should be considered only for rescue PCI.
•	 STEMI: High risk STEMI patients. The risks to the treating personnel should be considered before 
deciding on primary PCI. If PPE is available and the hospital cath lab personnel are well versed in 
its use, then consider primary PCI. In all other situations, thrombolysis should be the treatment of 
choice.
•	 Low risk NSTEMI: Conservative management.
Suspected COVID-19 infection presenting with ACS:
•	 STEMI: Thrombolysis should be the reperfusion strategy of choice, like in patients with confirmed 
COVID-19 cases.
•	 NSTEMI: Conservative management until the confirmatory test results are available. Timing should 
allow for diagnostic testing for COVID-19 before cardiac catheterization and allow for a more in-
formed decision regarding infection control.
◦  Patients with COVID-19 can have significant thrombocytopenia. This should be considered 
when deciding the revascularisation strategy [32].
Figure 2 summarizes the overall management of acute chest pain.
3. Myocardial injury
Myocardial injury, diagnosed by raised troponin is common in patients with moderate to severe COVID-19 
and is associate with poor prognosis. Although, myocarditis was initially proposed as a mechanism, it is 
increasingly clear that there is minimal inflammation on biopsy and autopsy studies. There are no viral 
Figure 2: Outcomes of acute chest pain [35]. Figure 2 adapted from ACC guideline Diagnosing Type 2 
Myocardial Infarction [35].
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particles in myocardium even though there is abundance of ACE2 receptors on myocardium and coronary 
vascular endothelium. The viral particles demonstrated in myocardium are contained within macrophages 
which have arrived from lungs. The overwhelming cause of injury in absence of CAD is proposed to be 
systemic cytokine response, micro vascular coagulation and demand ischemia. Cytokine storms lead to 
increased vascular permeability and myocardial oedema with transient damage to the myocardium [36–38]. 
Chinese expert consensus statements report that immunological damage is the predominant mechanism 
observed in adult patients and is associated with a more rapid recovery of cardiac function [39]. Figure 3 
outlines approach to a patient with myocardial injury. 
Figure 3: Diagnosis and management of myocardial injury in COVID-19 patients.
Legend: ACE, angiotensin converting enzyme; BNP, brain natriuretic peptide; CPAP, continuous positive 
airway pressure; ECG, electrocardiogram; EMB; endomyocardial biopsy; HCU, high care unit; hs-TnT, high 
sensitivity troponin T; ICU, intensive care unit; JVP, jugular venous pressure; MRA, mineralocorticoid 
receptor antagonists; MV, mitral valve; RA, right atrium; RV, right ventricle; TV, tricuspid valve.
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ECG in Patients with COVID-19: Sinus tachycardia is a common but non-specific finding in COVID-19 
patients and may be present in the absence of myocardial injury. Non-localizing ST changes (typically 
concave in shape) and/or non-specific T-wave changes are suggestive of underlying myocardial involvement. 
New conduction abnormalities, such as atrioventricular block, sinus arrest and QRS prolongation, and 
arrhythmias (atrial or ventricular) are suggestive of underlying cardiac involvement [40].
Chest Radiograph: Radiographically, it may be difficult to distinguish pulmonary oedema from 
viral pneumonia, however, some distinguishing features may be useful (Table 1). Radiographic 
findings should always be interpreted in conjunction with other clinical findings. Clinical or radio-
logical improvement after administration of diuretics may support the presence of pulmonary 
oedema. 
Cardiac structural and functional abnormalities: Ventricular dysfunction (systolic or diastolic) 
with or without dilatation of the ventricles indicates a significant myocardial insult. Regional wall 
motion abnormalities may be present and are supportive of myocarditis particularly when observed 
at rest and seen in combination with non-localizing ST changes on ECG and a positive troponin. 
Viral myocarditis frequently affects the basal infero-lateral wall. Additional features that may be pre-
sent include, increased ventricular wall thickness, pericardial effusion and intracardiac thrombus 
formation [40].
Management of myocardial injury in COVID-19 patients
Management of COVID-19 related myocardial injury is outlined in Figure 3. Current guidelines for the 
treatment of viral myocarditis should be applied, including the use of standard heart failure therapies and 
supportive measures [40, 43]. Prednisolone has shown some benefit in a few isolated case reports, how-
ever, there is insufficient evidence to support the routine use of steroids in these patients and may cause 
harm [44].
Thrombosis and anticoagulation 
COVID-19 infection has been associated with pro-thrombotic abnormalities [45]. Studies have shown that 
patients with COVID-19 might present with increased D-dimer levels, fibrin degradation products, and pro-
thrombin time (PT) prolongation; all changes that are associated with a higher risk of poor outcome [46]. 
These hemostatic changes indicate some forms of coagulopathy that may predispose to thrombotic events, 
Table 1: Chest radiographic findings in COVID-19 pneumonia and cardiogenic pulmonary oedema.
COVID-19 Pneumonia Cardiogenic Pulmonary Oedema
Typical:
– Peripheral bilateral ground glass opacities (GGO) 
with or without consolidation
– Multifocal GGO with rounded morphology
Typical (acute heart failure):
– Central, peri-hilar bilateral GGO with peripheral 
sparing (‘batwing distribution’)
– Interlobular septal thickening (Kerley B lines)
– Pleural effusions 
– Peri-bronchial cuffing
Additional features seen in chronic heart failure:




Absence of typical features AND the presence of:
– Multifocal, diffuse, perihilar or unilateral GGO 
with or without consolidation
Atypical:
– Isolated lobar or segmental consolidation without 
GGO
– Smooth interlobular septal thickening with 
pleural effusions
Atypical:
– Unilateral GGO, with or without pleural effusions
– Pulmonary pseudotumour (fluid within the interlobar 
fissure)
Courtesy of Vishesh Sood, Department of Radiology, Groote Schuur Hospital, South Africa.
Adapted from Simpson et al. Radiology: Cardiothoracic Imaging. 2020; 2(2): e200152 [41] and Gluecker et al. 
Radiographics. 1999; 19(6):1507–1531 [42].
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but whether these changes are a specific consequence of SARS-CoV-2 or a result of systemic inflammatory 
response syndrome (SIRS) is still uncertain [47].
As any hospitalized patients with an acute medical illness, patients with COVID-19 are at increased risk of 
venous thrombotic events and prophylactic anticoagulation is indicated to reduces their risk as indicated by 
clinical guidelines [48].
Based on the hemostatic changes observed in COVID-19, it has been hypothesized that anticoagulation 
(rather than prophylaxis) could be beneficial for patients with COVID-19. The evidence is only emerging, and 
there is some data showing that anticoagulation could indeed be beneficial [49–50]. However, the evidence 
so far is based on sub-group analyses of observational studies and further randomised controlled studies are 
needed to confirm or refute this hypothesis. 
Follow-up
There is currently no data available on the long-term sequelae of COVID-19 myocarditis. Current recommen-
dations for the management of other forms of viral myocarditis should be followed in the interim [40]. It is 
recommended that patients with structural and functional abnormalities have a repeat echocardiogram in 
1-3 months after discharge and are followed up for a minimum of six months. Where left ventricular (LV) 
recovery is delayed beyond three months, heart failure therapy should be continued for a minimum of six 
months to a year. Long-term therapy heart failure therapy is advised in patients with persistent LV dysfunc-
tion, conduction abnormalities, or those with evidence of myocardial scar.
4. Heart failure and COVID-19
Case fatality rate in patients with CVD including heart failure has been reported to be as high as 10.5% 
compared to fatality rate of 2.3% in the general population [51].
The management of heart failure (HF) patients with suspected or confirmed COVID-19 begins with 
recognizing that respiratory infection is a common trigger of HF decompensation. Patients with chronic 
cardiac conditions (including HF) are predisposed to respiratory infections and their complications with 
some symptoms and signs of both cardiac and respiratory conditions overlapping. An overarching consi-
deration in the management of such patients is the very high virulence and transmissibility of COVID-19, 
necessitating extraordinary efforts to minimize exposure for both patients and medical staff. 
Guidance during clinical evaluation and management
Stable patients with chronic heart failure (HF) may be followed up via telemedicine as far as possible, with 
elective procedures deferred, thus minimising their exposure to infection. Routine flu vaccination should be 
considered for these patients with chronic HF.
In unstable patients, presenting to the healthcare facility, protection to healthcare staff and other patients 
should be ensured during clinical evaluation. This includes adequate physical distancing, proper applica-
tion of PPE for both staff and patients, segregation of staff, wards and equipment as far as possible. For 
example, patient front-facing versus non-patient-facing teams, COVID-19 positive versus negative patients 
wards to minimize cross-contamination, thorough disinfection of equipment used for patient evaluation, 
restricting visitors and using virtual means to communicate with patients’ relatives as much as possible 
[52–53].
Clinical assessment should focus on history and physical examination, isolating patients until the diag-
nosis of COVID-19 is established or excluded and this may require repeated swab testing in cases of high 
pretest probability. Standard investigations in the evaluation of HF patients [54–55] should be considered 
with the following caveats:
1. Request only tests that are expected to change management or are potentially lifesaving. 
2. Conduct assessment at the patient’s bedside as much as possible. 
3. Circulating biomarkers, for example, natriuretic peptides and cardiac troponins that may facilitate 
differential diagnoses or risk stratification for further investigations should be prioritised.
4. Echocardiography where indicated should be conducted using a focussed protocol [52] and by 
point-of-care ultrasonography where available.*
5. In hemodynamically and electrically stable patients, routine angiography or advanced cardiac imaging 
may not be necessary or can be delayed.
6. Routine endomyocardial biopsy in patients with active COVID-19 is discouraged.
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Echocardiography should be used with adequate precautions for person and equipment to maintain barrier 
based on resources available. Considerations should focus on ‘Whom to Image’, ‘Where to Image’ and ‘How 
to Image’ with the aim to restrict transmissions [56].
Treatment of patients with heart failure and confirmed COVID-19 should include the following 
considerations:
1. Establish the patient goals of care via effective doctor-patient communication, for example e.g. prefer-
ence for cardiopulmonary resuscitation and ventilation.
2. Continuation of HF guideline-directed medical therapies is generally warranted despite controversies 
regarding the effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers 
on COVID-19 (coronaviruses gain entrance to cells via the ACE2 receptor, which might be upregulated 
by use of these therapies). Despite this, all major cardiology societies have recommended against the 
withdrawal of renin-angiotensin system inhibitors based on available data unless otherwise clinically 
indicated.
3. A multi-disciplinary team approach is encouraged, including an infectious disease consultant and 
intensive care specialist and pulmonologist. 
4. Given limited high-quality evidence and lack of universally accepted guidelines specific to the manage-
ment of COVID-19-related cardiac disease, enrolment in ongoing clinical trials is encouraged.
5. Among experimental approaches.
a.  Hydroxychloroquine has been proposed to treat COVID-19 based on in-vitro data and a small 
open-label study with significant methodological limitations, however further studies are war-
ranted. As mentioned above, it should be noted that hydroxychloroquine could prolong QT 
interval and cause arrhythmias.
b.  Antiviral therapies especially hold promise but need further study.
c.  Immunosuppression has been used as salvage therapy in selected cases, however given concerns 
that steroids may prolong viral persistence, steroid treatment is not routinely recommended in 
all cases.
d.  Anti-inflammatory agents e.g. interleukin-6 inhibitors are under investigation in patients with 
severe COVID-19.
e.  Convalescent plasma from recovered COVID-19 patients has been approved by the FDA and 
warrants further study.
6. Mechanical circulatory support may be indicated in selected patients with refractory shock.
7. Patients who recover from acute episodes should be closely followed up for any longer-term sequelae.
Other heart failure and COVID-19 considerations relevant in low resource 
settings
Rheumatic Heart disease
At this current stage there are no data on the vulnerability of patients with rheumatic heart disease (RHD) 
and the impact of COVID-19 infection. Patients with RHD are usually between ages 20s and 30s and may 
have left ventricular dysfunction or pulmonary hypertension making them more vulnerable to the com-
plicated COVID disease. Patients should be made aware of the consequences of infection and advised to 
observe social distancing. They should continue their usual medication even where they experience suspi-
cious symptoms for COVID-19 while awaiting test results. The World Heart Federation COVID cardiovascular 
disease survey (WHF-COVID) is planned to commence May 2020 and will hopefully provide much needed 
data. 
Chagas disease
There is limited information available about the risk of stable asymptomatic patients, therefore people with 
chagas disease should follow the same recommendations as general population. However, those with com-
plicated Chagas disease do have a higher risk because of the high prevalance of heart failure, as previously 
mentioned linked to higher risk of complications in patients with COVID-19. A decision should be made as 
to whether to suspend antiparasitic treatment and recommence once recovered from COVID-19.
Summary of Chagas disease severity and treatment recommendation:
1. Indeterminate form or without apparent cardiopathy.
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◦ Risk comparable to the general population;
◦ Suspension or delay of antiparasitic drugs if symptomatic COVID-19.
2. Chagas cardiopathy without heart failure.
◦ Higher arrhythmic risk (even if asymptomatic);
◦ Cautious use of medications that produce arrhythmias;
◦ Suspension or delay of antiparasitic drugs if symptomatic COVID-19.
3. Chagas cardiopathy with heart failure.
◦ Higher risk of death or complications related to the COVID-19;
◦ Higher arrhythmic risk;
◦ No indication for antiparasitic drugs use. 
Final comments 
The WHF Science Committee will continue to closely monitor the evolving nature of the data on COVID-
19 and its potential link with cardiovascular diseases. We strive to keep updating the latest information on 
the clinical implications of COVID-19 outbreak on cardiovascular diseases and organize webinars involving 
expert panelists to share experience of the front-line health workers managing COVID-19 and cardiovascular 
diseases. Furthermore, WHF COVID-19 CVD global survey will provide key insights to inform clinical and 
policy practices, for a better understanding of the cardiovascular conditions that increase the risk of develop-
ing severe COVID-19, and a better characterization of cardiovascular complications in hospitalized patients 
with COVID-19.
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